
Nobody Knew…Until the Diabetes Control and Complications Trial
The common belief for decades was that diligent monitoring of blood sugars and intensive insulin therapy had little consequence for people with diabetes. Then the Diabetes Control and Complications Trial (DCCT) took place. This trial, from 1983-1993, would find out if intensive insulin control warded off complications from the disease. (Hint: it does.) A lot […]

The Power of the Patient Voice: Breakthrough T1D Video
In the words of Colin Dayan, M.D., Ph.D., professor of clinical diabetes and metabolism at Cardiff University: “Type 1 diabetes is almost the only major autoimmune disease now that does not have a licensed immunotherapy.” And he’s going to change that.

Tandem Control-IQ Improves T1D Management in Children Ages 6 and Up
A clinical trial at four pediatric diabetes centers in the United States has found that a new artificial pancreas system—which automatically monitors and regulates blood-sugar levels—is safe and effective in children as young as age six with type 1 diabetes (T1D): Tandem’s t:slim X2™ insulin pump with Control-IQ™ technology. The algorithm in the Control-IQ technology […]

Breakthrough T1D Researchers Develop a Combined Risk Score to Predict Which Children Develop T1D
Type 1 diabetes (T1D) can be hard to predict in high risk children. Testing for the presence of T1D autoantibodies—antibodies against one’s own proteins—helps reduce the incidence of diabetic ketoacidosis (DKA)—a common occurrence in children upon diagnosis, that can lead to death if not treated—but this testing is not widely available. While having 2 or […]

At ADA, Breakthrough T1D-Funded Research Takes Center Stage (featuring a “Happy Hour” with Dr. Aaron Kowalski)
At the American Diabetes Association’s Scientific Sessions, which was held virtually from June 12-16, scientists presented on some of the most important topics, from artificial pancreas trials to immune therapy trials to prevention trials, all with the same goal: ending type 1 diabetes (T1D) and improving lives until that day comes. Breakthrough T1D played the […]

Dr. Jane Buckner Discusses Hydroxychloroquine T1D Prevention Study
Details about the TrialNet study, including why Hydroxychloroquine, and the status of subject participation.

At the Front Lines in COVID-19: Breakthrough T1D-Funded Scientist’s Company Developing a Vaccine
With coronavirus closing schools and forcing so many people to stay inside or wear facemasks every time they step outdoors, COVID-19 is threatening to make everyone stir-crazy well into summer. And unfortunately, the safety of herd immunity remains a long way off. In the meantime, scientists are battling coronavirus in a number of ways, and […]

Zucara Faces “Valley of Death,” and Comes Out Triumphant
Low blood sugar, called hypoglycemia, is a real fear for people with type 1 diabetes (T1D). Although there are rescue treatments for it, there are no preventive therapies. Zucara Therapeutics, however, may have an answer. It is developing a once-daily therapy that restores glucagon. Adding glucagon raises blood-sugar levels, preventing hypoglycemia and the symptoms that […]

Breakthrough T1D Awards World-Renowned T1D Researchers
Breakthrough T1D is honored to recognize five leading international researchers whose work has and is transforming type 1 diabetes (T1D) science. We also are proud that our funding has helped drive their work forward toward both curing type 1 diabetes and improving the lives of those living with the disease today. The recipient of the […]

Universal Screening for Type 1 Diabetes: Its Time has Come?
Universal screening for type 1 diabetes (T1D) is a priority for Breakthrough T1D, but the cost versus benefits remain unclear. Now, a large-scale population study in Bavaria, Germany, headed by Breakthrough T1D-funded Anette-Gabriele Ziegler, M.D., Ph.D., has a clue. The Fr1da study of nearly 100,000 children suggests that screening for autoantibodies—antibodies that are directed toward your […]